Loading Please wait, logging in.
Join ALFA Member Login RSS Feed
Tagline Image
Bookmark and Share  

Antipsychotics Beneficial For Some Individuals With Alzheimer’s

A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.

Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.

Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City.  “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."

For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study  Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.

 
Suggested Articles:

5/19/2016
CEO, cheatsheet, Clinical Quality and Quality Care Delivery, End of Life, Facts and Figures, Health and Wellness, Health Care, Medicare, Research, Wellness Program
The new Medicare system for reimbursing providers outlined in the Medicare Access and CHIP Reauthorization Act, or MACRA, may not adequately reward go...
5/12/2016
Argentum’s Memory Care Executive Peer Group with the support of MatrixCare has commissioned a new project to recognize innovations improving resident ...
5/10/2016
Advocacy, Choice, Clinical Quality and Quality Care Delivery, Core Principles, Dignity, Independence, Quality of Life, Regulations, Regulatory Compliance
Argentum launched the first phase of professional standards for operators of senior living communities this year and is looking to identify more compr...
5/9/2016
Argentum’s Memory Care Executive Peer Group with the support of MatrixCare has commissioned a new project to recognize innovations improving resident ...
5/4/2016
Memory Care Best Practices and Research, Memory Care Education, Reports
The aroma of rosemary essential oil reportedly can aid people over age 65 in their ability to remember events and to complete tasks at designated time...
5/4/2016
Advocacy, CEO, cheatsheet, Legislation, Medication Management, Policy in the States
Tennessee Gov. Haslam has signed Tennessee S.B. 2383 into law. This new law will enhance the services provided to residents who need assistance wit...
4/27/2016
Consumer Intelligence, End of Life, Facts and Figures, Health and Wellness, Reports
Over the next 15 years, adopting healthy behaviors, developing better treatments and improving access to high quality care for chronic disease would r...
4/27/2016
Disabilities, Facts and Figures, Falls Prevention, Managed Risk, Reports
An increasing number of people in Europe and North American are expected to use personal emergency response systems (PERS), growing at an annual compo...
4/27/2016
cheatsheet, Federal Agency Activity, Health and Wellness, Managed Risk, Memory Care Best Practices and Research, Memory Care Education
The Dementia Friendly America program entered the national stage in July when it was announced at the 2015 White House Conference on Aging. DFA cre...
4/20/2016
End of Life, Health Care, Reports
Physicians agree that talking with patients about end-of-life and advance care planning is important, but many also said they’re often unsure what to ...
   
10/23/2012


Additional Resources